Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis Turku, Finland, March 07 2019: Forendo Pharma, a clinical stage drug development company focusing on … Continue reading “Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis”
March 6, 2019. Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the appointment of Dan Furrer as Head of … Continue reading “European CNS specialist Neuraxpharm appoints Dan Furrer as Head of Corporate Marketing”
Dirk de Naeyer appointed Chief Operations Officer and Martine Nolan as Head of Quality Assurance, effective March 1, 2019 Amsterdam, The Netherlands, March 5, 2019 – Kiadis Pharma N.V. (“Kiadis … Continue reading “Kiadis Pharma Strengthens Management Team”
Geneva, Switzerland, 28th February 2019: iOnctura SA, a late stage preclinical immuno-oncology company, announced today that its abstract (abstract # 1781) entitled “Preclinical development of a novel, highly selective PI3Kδ … Continue reading “iOnctura selected for an oral presentation at 2019 AACR Annual Meeting”
Cambridge, UK – 27th February 2019 Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces it has received approval from … Continue reading “Nuformix Announces MHRA Approval to Commence NXP001 Human Pharmacokinetics Studies”
LOS ANGELES, Feb. 26, 2019 – ImaginAb, Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Ian Wilson as Chief Executive Officer while Martyn Coombs steps down for family reasons, effective immediately. … Continue reading “ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board”
LONDON, 19 February 2019: Arix Bioscience plc (LSE:ARIX) (“Arix” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that Chief Investment Officer, Joe Anderson, … Continue reading “Arix Bioscience announces Management and Board changes Joe Anderson appointed as CEO”
Funding rises for early assets MedNous Feb 2019 Published in the February 2019 edition of MedNous, a publication of Evernow Publishing Ltd … Continue reading “Meeting Report: Funding rises for early assets”
European CNS specialist Neuraxpharm strengthens French business Dr. Pierre-Hervé Brun appointed new General Manager of Neuraxpharm France Paris, February 14th, 2019. Neuraxpharm France, the French affiliate of Neuraxpharm Group, a … Continue reading “European CNS specialist Neuraxpharm strengthens French business”
Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that it will host its first … Continue reading “Futura Medical to hold its First European Advisory Panel Meeting at the European Society of Sexual Medicine (ESSM)”
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Primary biliary … Continue reading “Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis”
Cambridge, UK, 11 February 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of … Continue reading “Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director”
Guildford, UK – 06 February 2019: HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces today that it will present a poster … Continue reading “HOX THERAPEUTICS TO PRESENT AT 2019 AACR ANNUAL MEETING”
Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Autoimmune hepatitis … Continue reading “Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis”
Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer Amsterdam, The Netherlands, and Boston, Massachusetts, USA – February 4, 2019 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext … Continue reading “Kiadis Pharma appoints Dr. Robert Friesen as Chief Scientific Officer”
Biotech Showcase™ 2019: Targeting tau to tackle neurodegenerative diseases Without adequate treatments, neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain an important unmet medical burden for aging societies. In a … Continue reading “Watch Biotech Showcase 2019 interviews from Optimum clients Asceneuron & F2G”
Feb 1, 2019 On February 7, 2019, at 07:00am CET, Calliditas Therapeutics (“Calliditas”) will publish its business update for the full-year 2018. The company will also host a telephone conference, … Continue reading “Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report”
February 1st, 2019. Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), announces the acquisition of Farmax, a CNS specialty pharmaceutical … Continue reading “Neuraxpharm acquires Farmax to expand its pan-European footprint in Central and Eastern Europe”
LONDON, 29 January 2019 Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, today notes that Harpoon Therapeutics Inc. (“Harpoon”) has filed an amended … Continue reading “Arix Bioscience plc Update on Harpoon proposed IPO in the United States”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2019 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com